MDY Mdy Healthcare

RNS No 0049h
MEDISYS PLC
26 July 1999

                          Medisys PLC
                               
                   Sale of Sutures Business
                               
Medisys PLC ("Medisys") announces that it has sold its  Lukens
sutures  business  to  Surgical Specialties  Corporation  Inc.
("SSC"), a subsidiary of the Marmon Group, for a consideration
of US$2,100,000 in cash.  Medisys will use the net proceeds of
the disposal to repay bank borrowings.

SSC  has  acquired the assets of the Lukens sutures  business,
including fixed assets, inventory and goodwill. The  net  book
value of the assets acquired by SSC is approximately $773,000.
In  accordance with standard accounting practice, Medisys will
record as a charge in its profit and loss account the goodwill
attributable  to  the  acquisition of  the  sutures  business.
Under  the terms of the transaction SSC has also acquired  the
Lukens  Medical name.   The remaining Lukens business will  be
retained  by  Medisys  and  will be  re-named  Futura  Medical
Corporation.

The   Futura  Medical  Corporation  product  range  will   now
concentrate  on  sharps bins, lancets, safety  scalpels,  bone
wax,  the  NIC  needle incineration device  and  the  recently
acquired Futura safety needle.  The company is also evaluating
other  products,  which  would enhance  the  existing  product
range.

Kurt  E.  Amundson,  President & Chief  Operating  Officer  of
Medisys said: "Disposal of the sutures business removes a loss
making, non-core business from our portfolio and completes the
restructuring  of the Lukens business, which  we  acquired  in
September   1998.   The  renamed  Futura  Medical  Corporation
business  will  be tightly focused on the fast growing  market
for   healthcare  worker  safety  devices  and  safe  disposal
systems."

Note to editors:

Medisys  PLC  develops, manufactures and  markets  diagnostic,
medical  and safety products serving the rapid test and  point
of care medical market.  The Group has two principal operating
subsidiaries, Hypoguard and Futura, located in the UK  and  in
the  US  respectively.  The diagnostic division  develops  and
supplies  blood  glucose monitoring systems for  the  diabetic
market.   Its  future focus is on serving unmet medical  needs
through  the development of diagnostic products based  on  its
own  proprietary  platform  technologies.   Headquartered   in
Ipswich, UK, the Group employs approximately 225 people in the
UK and US.

Enquiries:

Medisys PLC
Kurt Amundson, President 
& Chief Operating Officer                     001 650 327 7900
Michael Barry, Chief Financial Officer       001 770  271 2795

Square Mile Communications                       0171 601 1000
Kevin Smith/James Melville-Ross


END

DISNFDXKADDNEFN

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024